SCHEMBL2969098

SCHEMBL2969098

COc1ccc(C(=O)Nc2cc(C(=O)NCCC3=CCCCC3)ccc2C)cc1OC

nearest known ligand 0.81

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.81
ALDH1A1 P00352 9/20 0.63
KMT2A Q03164 2/20 0.63
GAA P10253 1/20 0.63
SMN1; SMN2 Q16637 6/20 0.60
NPC1 O15118 6/20 0.60
SLC5A7 Q9GZV3 1/20 0.59
HPGD P15428 1/20 0.58
LMNA P02545 3/20 0.57
NPSR1 Q6W5P4 2/20 0.57
HTT P42858 1/20 0.57
MAPT P10636 2/20 0.56
KDM4E B2RXH2 1/20 0.56
MEN1 O00255 1/20 0.55
NFKB1 P19838 1/20 0.52
NFKB2 Q00653 1/20 0.52
RELA Q04206 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14650866 0.81 RAB9A (0.83) RAB9AALDH1A1KMT2AGAASMN1; SMN2
SCHEMBL16299058 0.78 RAB9A (0.77) RAB9AALDH1A1KMT2AGAASMN1; SMN2
SCHEMBL2978657 0.77 LDLR (0.74) KMT2AMEN1
SCHEMBL2969095 0.76 LDLR (0.52) RAB9A
SCHEMBL241870 0.75 MAPK14 (0.58) KMT2AKDM4EMEN1
SCHEMBL10016407 0.75 SLC5A7 (1.00) RAB9AALDH1A1KMT2AGAASLC5A7
SCHEMBL3456825 0.74 RAB9A (1.00) RAB9AALDH1A1KMT2AGAASMN1; SMN2
SCHEMBL2969970 0.74 KDM4E (0.67) RAB9AALDH1A1KMT2ASMN1; SMN2NPC1
SCHEMBL2979309 0.74 CA12 (0.64) ALDH1A1KMT2AGAAHPGDMAPT
SCHEMBL14650868 0.73 SLC5A7 (0.69) RAB9AALDH1A1KMT2AGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772432-B2 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA AB (SE) 2010-08-10 US disclosed
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA 2005-02-17 US disclosed
US-6821965-B1 IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION ASTERZENECA AB (SE) 2004-11-23 US disclosed
EP-1102743-B1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2002-07-24 EP disclosed
EP-1102743-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS AstraZeneca AB (SE) 2001-05-30 EP disclosed
WO-2000007980-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors IL6, IL6ST, IL2 RAB9A 1437/4885ALDH1A1 293/4885KMT2A 1554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.